NEW YORK (GenomeWeb News) – The ALS Emergency Treatment Fund and Denovo Biomarkers today announced a partnership to evaluate Denovo's technology to identify patients who may best respond to amyotrophic lateral sclerosis drugs being studied.

The partnership will use Denovo's pharmacogenomic technology in order to identify biomarkers from biological samples from expanded access programs sponsored by ALS-ETF. Biomarkers which can be correlated with patient response to treatments may then be used to identify patient subsets for subsequent trials, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.